摩熵化学
数据开放平台 数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-aminoquinazoline-7-carboxylic Acid | 1017385-11-3

中文名称
——
中文别名
——
英文名称
4-aminoquinazoline-7-carboxylic Acid
英文别名
——
4-aminoquinazoline-7-carboxylic Acid化学式
CAS
1017385-11-3
化学式
C9H7N3O2
mdl
——
分子量
189.17
InChiKey
LLWPSTZOWBGKFK-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.8
  • 重原子数:
    14
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    89.1
  • 氢给体数:
    2
  • 氢受体数:
    5

文献信息

  • SIX-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS
    申请人:Bristol-Myers Squibb Company
    公开号:EP1773775B1
    公开(公告)日:2011-08-17
  • FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS
    申请人:Bristol-Myers Squibb Company
    公开号:EP1773786B1
    公开(公告)日:2017-04-26
  • SUBSTITUTED BIARYL COMPOUNDS AS FACTOR XIA INHIBITORS
    申请人:Bristol-Myers Squibb Company
    公开号:EP1841504B1
    公开(公告)日:2014-11-19
  • [EN] FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS<br/>[FR] HETEROCYCLES A CINQ CHAINONS UTILISES COMME INHIBITEURS DE LA SERINE PROTEASE
    申请人:BRISTOL MYERS SQUIBB CO
    公开号:WO2005123050A2
    公开(公告)日:2005-12-29
    The present invention provides a method for treating a thrombotic or an inflammatory disorder administering to a patient in need thereof a therapeutically effective amount of at least one compound of Formula (I) or Formula (V): (I) [INSERTCHEMICAL STRUCTURE HERE] (V)[INSERT CHEMICAL STRUCTURE HERE] or a stereoisomer or pharmaceutically acceptable salt or solvate form thereof, wherein the variables A, L, Z, R3, R4, R6, R11, X1, X2, and X3 are as defined herein. The compounds of Formula (I) are useful as selective inhibitors of serine protease enzymes of the coagulation cascade and/or contact activation system; for example thrombin, factor Xa, factor XIa, factor IXa, factor VIIa and/or plasma kallikrein. In particular, it relates to compounds that are selective factor XIa inhibitors. This invention also provides compounds within the scope of Formula I and relates to pharmaceutical compositions comprising these compounds.
查看更多